Emergex Awarded £490,525 UK Aid Grant by the Department of Health and Social Care to Advance Synthetic T cell Vaccine Candidate for Chikungunya Virus
22 févr. 2022 02h00 HE
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Awarded £490,525 UK Aid Grant by the Department of Health and Social Care to Advance Synthetic T cell Vaccine Candidate for Chikungunya Virus Abingdon, Oxon, UK, 22 February...
Emergex confirms its next generation T-Cell Priming COVID-19 vaccine candidate has the potential to be effective against all currently sequenced viral mutations
30 nov. 2021 08h51 HE
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex confirms its next generation T-Cell Priming COVID-19 vaccine candidate has the potential to be effective against all currently sequenced viral mutations Emergex confirms that...
Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate
15 nov. 2021 07h00 HE
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate Synthetic vaccine designed to prime T-Cells to rapidly remove...
Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate
15 nov. 2021 02h00 HE
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate Synthetic vaccine designed to prime T-Cells to rapidly remove...
Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue of a T-Cell Priming Vaccine
30 juin 2021 02h00 HE
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue of a T-Cell Priming Vaccine Swiss regulatory authorities, including the Swiss Agency for Therapeutic...
Emergex Strengthens Senior Management Team
23 févr. 2021 02h00 HE
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Strengthens Senior Management Team Appointments of Mr Robin Cohen as Business Development Director and Ms Susi Osborne as Manufacturing Director Abingdon, Oxon,...
Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
05 janv. 2021 07h00 HE
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine Agreement provides a framework for future clinical...
Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
05 janv. 2021 02h00 HE
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine Agreement provides a framework for future clinical...
Emergex Vaccines Raises US$11 million to Advance Pipeline of Synthetic T-Cell Vaccines for Infectious Diseases
18 nov. 2020 02h00 HE
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Vaccines Raises US$11 million to Advance Pipeline of Synthetic T-Cell Vaccines for Infectious Diseases Investor support further endorsement of vaccine development strategy...
Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells
15 sept. 2020 07h00 HE
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells First detailed, empirical analysis of Class 1 epitopes presented by...